Idiopathic pulmonary fibrosis: The current state of the problem


Cite item

Full Text

Abstract

Idiopathic pulmonary fibrosis (IPF) is a severe lung disease, with death occurring within 2-5 years after its onset. IPF affects people in the second half of life. Its causes are unknown. Before 1999, IPF was out from the group of idiopathic interstitial lung diseases as a separate nosological entity. Practitioners very often (80%) make diagnostic errors in IPF and prescribe antibiotics, anti-inflammatory drugs, which worsen the course of this disease. The distinctive feature of the pathogenesis of IPF is the absence of inflammation, which is clinically manifested by the inefficacy of glucocorticosteroids and other anti-inflammatory drugs. Pharmacological agents for the treatment of IPF have been designed since 2000. One of them has been registered and permitted for use in the Russian Federation. This paper is a review of an update on the problem of IPF, which should facilitate the appropriate orientation of physicians in diagnosing and treating this severe disease.

About the authors

E I Shmelev

References

  1. American Thoracic Society/European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165:277-304. doi: 10.1164/ajrccm.165.2.ats01
  2. Raghu G, Wwycker D, Edelberg J et al. Incidence and prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2006;174:810-816. doi: 10.1164/rccm.200602-163OC
  3. Idiopathic Pulmonary Fibrosis: Diagnocis and Treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161:646-664. doi: 10.1164/ajrccm.161.2.ats3-00
  4. Raghu G, Collard HR, Egan JJ et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. doi: 10.1164/rccm.2009-040GL
  5. Luppi F, Spagnolo P, Cerri S, Richeldi L. The big clinical trials in Idiopathic Pulmonory Fibrosis. Curr Opin Pulm Med. 2012;18;428-432. doi: 10.1097/MCP.0b013e3283567ff9
  6. Raghu G, Anstrom KJ, King TE et al. Idiopathic Pulmonory Fibrosis Clinical Research Network. Prednisolone, azatioprine- and N-acetylcystein for pulmonary fibrosis. N EnglJ. 2012;366;1968-1977. doi: 10.1056/NEJMoa1113354
  7. Raghu G, Bram R, Yuan Z et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonory Fibrosis: Executive Summary/ Update of the. 2011 Clinical Practice Guideline Am J Respir Crit Care Med. 2015;192(2):237-248. doi: 10.1164/rccm.201506-1063ST
  8. Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Части 1 и 2. ConsiliumMedicum. 2014;Болезни органов дыхания(Приложение):4-9.
  9. Sandbo N. Mechanismis of fibrosis in IPF. in book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014:161-205. doi: 10.1007/978-1-62703-682-5_8
  10. Beers MF, Morrisey EE. The three Rs of lung health and disease: repair, remoduling, and regeneranion. J Clin Invest. 2011;121(6): 2065-2073. doi: 10.1172/JCI45961
  11. Tiery JP, Sleeman JP Cjmplex networks orhestrate epithelial-mesenchimal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142. doi: 10.1038/nrm1835
  12. Cool CD, Groshong SD, Rai PR et al. Fibroblast foci are not discrete sites оf lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006;174 (6):654-658. doi: 10.1164/rccm.200602-205OC
  13. Marinkovic A, Mih JD, Park JA et al. Improved throughput traction microscopy reveals pivotal role fore matrix stiffness in fibroblast cobtracyiluny and TGF-beta responsiveneaa. Am J Phisiol Lung Cell Mol Physiol. 2012;303(3):169-180. doi: 10.1152/ajplung.00108.2012
  14. Raghu G, Collard HR, Egan JJ, and ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. doi: 10.1164/rccm.2009-040GL
  15. Ryu JH, Moua T, Daniels CE et al. Idiopathic pulmonary fibrosis:Evolving concepts. Mayo Clin Proc. 2014;89:1130-1142. doi: 10.1016/j.mayocp.2014.03.016
  16. Tobin RW, PopeCE, Pellegrini CA et al. Increse prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804-1808. doi: 10.1164/ajrccm.158.6.9804105
  17. Raghu G, Yang ST, Spada C at al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129:794-800. doi: 10.1378/chest.129.3.794
  18. Lettieri CJ, Nathan SD, Barnett S at al. Chest. 2006;129:746-752. doi: 10.1378/chest.129.3.746
  19. Lancaster LH, Mason WR, Parnell JA at al. Chest. 2009;136:772-778. doi: 10.1378/chest.08-2776
  20. Brown AW, Shlobin OA, Weir N, at al. Dinamic patient counseling: A novel concept in idiopathic pulmonary fibrosis. Chest. 2012;142:1005-1010. doi: 10.1378/chest.12-0298
  21. Selman M, Carillo G, Estrada A et al. Accelerated variantof idiopathic pulmonary fibrosis. PloS One. 2007;2:(57):e482. doi:org/10.1371/journal.pone.0000482
  22. Trujiillo G, Meneghin A, Flahertty KR et al. Sci Transl Med. 2010;2(57):ra82. doi: 10.5214/ans.0972.7531.210407
  23. Collard HR, Moore BB,Flaherty KR et al. Acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-643. doi: 10.1164/ajrccm.177.12.1398
  24. Lee JS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science: N York; 2014;349-358. doi: 10.1007/978-1-62703-682-5_17
  25. Wadhwa A, Flaherty KR The keys to making a confident diagnosis of IPF. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;77-101. doi: 10.1007/978-1-62703-682-5_5
  26. Wells AU, Ward S. Pulmanary Function tests in Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;103-121. doi: 10.1007/978-1-62703-682-5_6
  27. Gibson GJ. Clinical tests of respiratory function London: Chappel and Hall; 1996:233-234. doi: 10.1007/978-1-349-81333-9_9
  28. Welss AU, Desai SR, Rubens MB et al. Idiopathic Pulmonory Fibrosis: a cjmposite phisiologic index derived from disease extend observed on computer tomography. Am J Respir Crit Care Med. 2003;167:962-969. doi: 10.1164/rccm.2111053
  29. Wells AU, Ward S. Pulmanary Function tests in Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;114. doi: 10.1007/978-1-62703-682-5_6
  30. Hunninghake GW, Zimmerman MB, Schwartz DA et al. Utility of lung biopsy for diagnosis of Idiopathic Pulmonory Fibrosis. Am J Respir Crit Care Med. 2001;164 (2):193-196. doi: 10.1164/ajrccm.164.2.2101090
  31. Utz JP, Ryu JH, Douglas WW et al. High short-term mortality following lung biopssy for usual interstitial pneumonia. Eur Resp J. 2001;17(2):175-179. doi: 10.1183/09031936.01.17201750
  32. Lettieri Cj, Veerapan GR, Helman DL et al. Chest. 2005;127(5):1600-1605. doi: 10.1378/chest.127.5.1600
  33. Canver CC, Mencer Jr RM. The role of open lung biopsy in early and late survival of ventilator-depends patients with diffuse idiopatic lung disease. J Cardiovassc Surg (Torino). 1994;35(2):151-155. doi: 10.1016/S0031-3025(16)39212-1
  34. Athol U. Wells Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Resp Rev. 2013;22:128,158-162. doi: 10.1183/09059180.00001213
  35. Richeldi L, Cjstabel U, Selman M et al. Efficacy of a tyrosine kinase ingibitor in Idiopathic Pulmonory Fibrosis. N Engl J Med. 2011;365:1079-1087. doi: 10.1056/NEJMoa1103690
  36. Wollin L et al. Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis. J Pharmacol Exp Ther. 2014;349:209-220. doi: 10.1124/jpet.113.208223
  37. Noble PW et al. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377:1760-1769. doi: 10.1016/S0140-6736(11)60405-4
  38. King TE et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092. doi: 10.1056/NEJMoa1402582
  39. Azuma A et al. Double- blind, placebo-controlled trial of pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047. doi: 10.1517/13543784.14.11.1443
  40. Taniguchi H et al. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J. 2010;35:821-829. doi: 10.1183/09031936.00005209
  41. Raghu G, Yang ST, Spada C et al. Outcomes of atypical symptoms attributed to gastroesophageal reflux. Chest. 2006;129(3):794-800. doi: 10.1378/chest.129.3.794
  42. Holland AE, Swigris DO. The role of pulmonary Rehabilitation and supplemental oxygen therapy in the treatment of patients with Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;337-347. doi: 10.1007/978-1-62703-682-5_16
  43. Lamas DJ, Lederer DJ. Lung transplantation for Idiopathic Pulmonory Fibrosis. In book: Idiopathic Pulmonory Fibrosis: A Comprehancive Clinical Guide. Springer Science. N York; 2014;363-377. doi: 10.1007/978-1-62703-682-5_18

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies